Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Anders

Showing results (201-210 of 247) with videos related to

Pageof 25
Sort By:
Pediatric Blood & Cancer|September 17, 2013
Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing ProgramHernan Carol, Richard Gorlick, E Anders Kolb, et al.
Frontiers in Cardiovascular Medicine|July 1, 2024
Cardiotoxicity of CPX-351 in children and adolescents with relapsed AML: a Children's Oncology Group reportKasey J Leger, Michael J Absalon, Biniyam G Demissei, et al.
Scientific Reports|August 27, 2024
Whole genome and reverse protein phase array landscapes of patient derived osteosarcoma xenograft modelsChia-Chin Wu, Licai Huang, Zhongting Zhang, et al.
Cancer|November 20, 2023
Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemiaJenny Ruiz, Yimei Li, Lusha Cao, et al.
Blood Advances|October 20, 2020
Morphologic remission status is limited compared to ΔN flow cytometry: a Children's Oncology Group AAML0531 reportLisa Eidenschink Brodersen, Robert B Gerbing, M Laura Pardo, et al.
Pediatric Blood & Cancer|October 1, 2021
Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology GroupCaitlin W Elgarten, Andrew C Wood, Yimei Li, et al.
Blood Advances|January 31, 2024
Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemiaKatherine Tarlock, Robert B Gerbing, Rhonda E Ries, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2022
Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio <i>FLT3</i>/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031Jessica A Pollard, Todd A Alonzo, Robert Gerbing, et al.
Blood|July 28, 2021
High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trialJohann Hitzler, Todd Alonzo, Robert Gerbing, et al.
Leukemia|February 15, 2019
Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemiaNicole A McNeer, John Philip, Heather Geiger, et al.
Pageof 25

Showing results (201-210 of 247) with videos related to

Sort By:
Pageof 25
Pediatric Blood & Cancer|September 17, 2013
Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing ProgramHernan Carol, Richard Gorlick, E Anders Kolb, et al.
Frontiers in Cardiovascular Medicine|July 1, 2024
Cardiotoxicity of CPX-351 in children and adolescents with relapsed AML: a Children's Oncology Group reportKasey J Leger, Michael J Absalon, Biniyam G Demissei, et al.
Scientific Reports|August 27, 2024
Whole genome and reverse protein phase array landscapes of patient derived osteosarcoma xenograft modelsChia-Chin Wu, Licai Huang, Zhongting Zhang, et al.
Cancer|November 20, 2023
Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemiaJenny Ruiz, Yimei Li, Lusha Cao, et al.
Blood Advances|October 20, 2020
Morphologic remission status is limited compared to ΔN flow cytometry: a Children's Oncology Group AAML0531 reportLisa Eidenschink Brodersen, Robert B Gerbing, M Laura Pardo, et al.
Pediatric Blood & Cancer|October 1, 2021
Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology GroupCaitlin W Elgarten, Andrew C Wood, Yimei Li, et al.
Blood Advances|January 31, 2024
Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemiaKatherine Tarlock, Robert B Gerbing, Rhonda E Ries, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2022
Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio <i>FLT3</i>/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031Jessica A Pollard, Todd A Alonzo, Robert Gerbing, et al.
Blood|July 28, 2021
High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trialJohann Hitzler, Todd Alonzo, Robert Gerbing, et al.
Leukemia|February 15, 2019
Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemiaNicole A McNeer, John Philip, Heather Geiger, et al.
Pageof 25